• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

    2/2/23 5:16:53 PM ET
    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AXLA alert in real time by email
    SC 13G/A 1 d441574dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)

     

     

    Axcella Health Inc.

    (Name of Issuer)

    Common Stock, par value $0.001

    (Title of Class of Securities)

    05454B105

    (CUSIP Number)

    Nestlé S.A.

    Avenue Nestlé, 55

    1800 Vevey

    Switzerland

    Attention: General Counsel

    Facsimile: 011-41-21-924-2821

    with a copy to: 

    David A. Carpenter, Esq.

    Mayer Brown, LLP

    1221 Avenue of the Americas

    New York, New York 10020

    (212) 506-2195

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 05454B105

     

      1.    

      NAME OF REPORTING PERSON:

     

      Société des Produits Nestlé S.A.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY:

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION:

     

      Switzerland

    NUMBER OF

    SHARES

     BENEFICIALLY 

    BY OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.    

      SOLE VOTING POWER:

     

      0

       6.  

      SHARED VOTING POWER:

     

      11,105,438

       7.  

      SOLE DISPOSITIVE POWER:

     

      0

       8.  

      SHARED DISPOSITIVE POWER:

     

      11,105,438

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      11,105,438

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

      15.09% (1)

    12.  

      TYPE OF REPORTING PERSON:

     

      CO

     

    (1) 

    Based upon a total of 73,554,837 shares of Common Stock outstanding as of October 28, 2022, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 1, 2022.


    CUSIP No. 05454B105

     

      1.    

      NAME OF REPORTING PERSON:

     

      Nestlé S.A.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY:

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION:

     

      Switzerland

    NUMBER OF

    SHARES

     BENEFICIALLY 

    BY OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5.    

      SOLE VOTING POWER:

     

      0

       6.  

      SHARED VOTING POWER:

     

      11,105,438

       7.  

      SOLE DISPOSITIVE POWER:

     

      0

       8.  

      SHARED DISPOSITIVE POWER:

     

      11,105,438

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

      11,105,438

    10.  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES:

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

      15.09% (1)

    12.  

      TYPE OF REPORTING PERSON:

     

      CO

     

    (1) 

    Based upon a total of 73,554,837 shares of Common Stock outstanding as of October 28, 2022, as reported by the Issuer in its Form 10-Q filed with the SEC on November 1, 2022.


    Item 1(a).   

    Name of Issuer:

     

    Axcella Health Inc.

    Item 1(b).   

    Address of Issuer’s Principal Executive Offices:

     

    840 Memorial Drive

    Cambridge, MA 02139

    (857) 320-2200

    Item 2(a).   

    Name of Person Filing:

     

    This statement is filed by:

     

    Société des Produits Nestlé S.A. (“SPN”), a société anonyme organized under the laws of Switzerland, with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by it.

     

    Nestlé S.A. (“Nestlé”), a société anonyme organized under the laws of Switzerland, with respect to the shares of Common Stock held by SPN, which is a wholly owned indirect subsidiary. The ultimate parent company of SPN is Nestlé.

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

    Item 2(b).   

    Address of Principal Business Office or, if none, Residence:

     

    The principal executive office of SPN and Nestlé is Avenue Nestlé 55, CH-1800, Vevey Switzerland.

    Item 2(c).   

    Citizenship:

     

    SPN and Nestlé are société anonymes organized under the laws of Switzerland.

    Item 2(d).   

    Title of Class of Securities:

     

    Common Stock, $0.001 par value per share (the “Common Stock”)

    Item 2(e).   

    CUSIP Number:

     

    05454B105

    Item 3.    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); and
       (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(J).


    Item 4.    Ownership.
      

    The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentage is based upon a total of 73,554,837 shares of Common Stock outstanding as reported by the Issuer in its Quarterly Report on Form 10-Q for the period ending September 30, 2022, as filed with the SEC on November 1, 2022.

     

    SPN is a wholly owned subsidiary of Nestlé and the ultimate parent company of SPN is Nestlé. Each of SPN and Nestlé may be deemed to share voting and investment power with respect to all shares of Common Stock held by SPN. Nestlé disclaims beneficial ownership of such shares of Common Stock except to the extent of its pecuniary interest therein.

    Item 5.    Ownership of Five Percent or Less of a Class.
       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
       Not applicable.
    Item 8.    Identification and Classification of Members of the Group.
       Not applicable.
    Item 9.    Notice of Dissolution of Group.
       Not applicable.
    Item 10.    Certifications.
      

    Each of the Reporting Persons hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated February 2, 2023

     

    SOCIETE DES PRODUITS NESTLE S.A.
    By:  

    /s/ Claudio Kuoni

      Name: Claudio Kuoni
      Title: Vice President
    NESTLÉ S.A.
    By:  

    /s/ Gregory Behar

      Name: Gregory Behar
      Title: Deputy Executive Vice President
    Get the next $AXLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXLA

    DatePrice TargetRatingAnalyst
    11/16/2021$10.00 → $12.00Buy
    Chardan Capital
    10/12/2021$6.00Outperform
    Noble Capital Markets
    9/22/2021$9.00 → $5.00Buy → Neutral
    Goldman Sachs
    7/30/2021Neutral → Underweight
    JP Morgan
    7/6/2021$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Axcella Health with a new price target

      Chardan Capital reiterated coverage of Axcella Health with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      11/16/21 9:26:58 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Noble Capital Markets initiated coverage on Axcella Health with a new price target

      Noble Capital Markets initiated coverage of Axcella Health with a rating of Outperform and set a new price target of $6.00

      10/12/21 8:46:44 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Axcella Health from Buy to Neutral and set a new price target of $5.00 from $9.00 previously

      9/22/21 6:18:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axcella Announces Reverse Stock Split Effective September 19, 2023

      – AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on Septembe

      9/14/23 4:30:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Granted Patent for Long COVID Fatigue Treatment

      Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticip

      8/29/23 8:00:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Reports Second Quarter Financial Results and Provides Business Update

      AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 The Company continues to pursue a strategic alternative for stakeholders Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. "Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue is potentially an important step to help people mainta

      8/3/23 7:30:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Koziel Margaret

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:54 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Fehlner Paul

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:17:30 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Hinshaw William

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:21 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Financials

    Live finance-specific insights

    See more
    • Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

      Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E. Axcella to host a conference call February 16 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. F

      2/15/23 4:10:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference

      Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities' 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023. Details for Axcella's participation are as follows: Date:   Thursday, February 16, 2023 Time:   11:20 am Eastern Time Webcast:   https://wsw.com/webcast/svb8/axla/1608786 The conference call webcast will be accessible in the Investors & News section on the company's website at www.axcellatx.com. An archive

      2/9/23 4:45:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

      MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial submitted to the FDA Axcella to host a conference call Tuesday, January 24 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U

      1/23/23 4:15:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Axcella Health Inc.

      25-NSE - Axcella Health Inc. (0001633070) (Subject)

      2/15/24 8:54:23 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/22/23 4:30:17 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/19/23 4:45:12 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      9/11/23 8:23:54 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      2/14/23 6:06:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      2/9/23 8:23:46 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

      Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

      4/11/22 6:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations